Thermo Fisher Scientific Inc. $TMO Shares Sold by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,810 shares of the medical research company’s stock after selling 1,000 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Thermo Fisher Scientific were worth $7,425,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Van Hulzen Asset Management LLC purchased a new position in Thermo Fisher Scientific in the second quarter worth approximately $260,000. MCF Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 11.3% in the 2nd quarter. MCF Advisors LLC now owns 7,978 shares of the medical research company’s stock valued at $4,003,000 after buying an additional 807 shares during the period. National Pension Service grew its holdings in Thermo Fisher Scientific by 1.5% during the 2nd quarter. National Pension Service now owns 841,947 shares of the medical research company’s stock worth $422,119,000 after acquiring an additional 12,295 shares in the last quarter. WINTON GROUP Ltd acquired a new position in shares of Thermo Fisher Scientific during the second quarter worth $14,219,000. Finally, Engineers Gate Manager LP increased its holdings in shares of Thermo Fisher Scientific by 207.4% in the 2nd quarter. Engineers Gate Manager LP now owns 18,701 shares of the medical research company’s stock valued at $9,376,000 after acquiring an additional 12,617 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $610.97 on Friday. The stock has a market capitalization of $225.90 billion, a price-to-earnings ratio of 32.87, a PEG ratio of 2.52 and a beta of 0.85. The company’s 50-day simple moving average is $580.40 and its 200-day simple moving average is $518.55. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $647.00.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same period in the prior year, the company posted $4.28 EPS. The business’s revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Analyst Ratings Changes

A number of brokerages recently weighed in on TMO. Stifel Nicolaus set a $650.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday, August 5th. Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday. Morgan Stanley raised their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Sanford C. Bernstein began coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price target on the stock. Finally, Citigroup downgraded Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $624.64.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc Casper sold 275 shares of the firm’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $627.05, for a total value of $172,438.75. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $77,707,171.25. This trade represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the sale, the vice president owned 14,784 shares in the company, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 73,768 shares of company stock valued at $44,122,820 over the last three months. Corporate insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.